Laboratory Corp. of America Holdings (NYSE:LH) reached a new 52-week high on Tuesday . The company traded as high as $136.68 and last traded at $136.50, with a volume of 255,687 shares. The stock had previously closed at $135.55.

A number of research firms have recently weighed in on LH. Morgan Stanley restated a “buy” rating on shares of Laboratory Corp. of America Holdings in a research report on Monday, May 2nd. Mizuho boosted their target price on Laboratory Corp. of America Holdings from $119.00 to $132.00 and gave the stock a “neutral” rating in a research report on Tuesday, April 26th. Canaccord Genuity boosted their target price on Laboratory Corp. of America Holdings from $135.00 to $140.00 and gave the stock a “buy” rating in a research report on Tuesday, April 26th. TheStreet upgraded Laboratory Corp. of America Holdings from a “hold” rating to a “buy” rating in a research report on Monday, March 14th. Finally, Credit Suisse Group AG began coverage on Laboratory Corp. of America Holdings in a research report on Tuesday, March 15th. They set an “outperform” rating and a $133.00 target price for the company. Six equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $135.50.

The stock has a market capitalization of $13.99 billion and a P/E ratio of 23.69. The firm has a 50-day moving average of $129.25 and a 200-day moving average of $119.40.

Laboratory Corp. of America Holdings (NYSE:LH) last announced its quarterly earnings results on Monday, April 25th. The company reported $2.02 EPS for the quarter, beating the Zacks’ consensus estimate of $1.96 by $0.06. During the same quarter in the previous year, the company posted $1.73 earnings per share. The firm earned $2.30 billion during the quarter, compared to the consensus estimate of $2.19 billion. The firm’s revenue was up 29.5% on a year-over-year basis. Equities analysts anticipate that Laboratory Corp. of America Holdings will post $8.79 EPS for the current fiscal year.

In related news, CEO David P. King sold 196,400 shares of the firm’s stock in a transaction on Monday, June 13th. The stock was sold at an average price of $128.00, for a total transaction of $25,139,200.00. Following the completion of the transaction, the chief executive officer now directly owns 271,210 shares of the company’s stock, valued at approximately $34,714,880. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Edward T. Dodson sold 9,392 shares of the firm’s stock in a transaction on Wednesday, April 27th. The stock was sold at an average price of $126.42, for a total value of $1,187,336.64. Following the transaction, the insider now directly owns 2,717 shares of the company’s stock, valued at $343,483.14. The disclosure for this sale can be found here.

Other hedge funds and institutional investors recently made changes to their positions in the company. Mutual of America Capital Management LLC raised its position in shares of Laboratory Corp. of America Holdings by 0.5% in the fourth quarter. Mutual of America Capital Management LLC now owns 11,272 shares of the company’s stock valued at $1,394,000 after buying an additional 61 shares in the last quarter. American National Bank & Trust Co. VA raised its position in shares of Laboratory Corp. of America Holdings by 1.0% in the fourth quarter. American National Bank & Trust Co. VA now owns 27,418 shares of the company’s stock valued at $3,390,000 after buying an additional 274 shares in the last quarter. Advantus Capital Management Inc raised its position in shares of Laboratory Corp. of America Holdings by 3.5% in the fourth quarter. Advantus Capital Management Inc now owns 9,796 shares of the company’s stock valued at $1,211,000 after buying an additional 332 shares in the last quarter. US Bancorp DE raised its position in shares of Laboratory Corp. of America Holdings by 1.3% in the fourth quarter. US Bancorp DE now owns 41,958 shares of the company’s stock valued at $5,187,000 after buying an additional 555 shares in the last quarter. Finally, Smith Salley & Associates raised its position in shares of Laboratory Corp. of America Holdings by 1.3% in the fourth quarter. Smith Salley & Associates now owns 47,588 shares of the company’s stock valued at $5,884,000 after buying an additional 630 shares in the last quarter.

Laboratory Corporation of America Holdings is a healthcare diagnostics company. The Company, together with its subsidiaries, is engaged in providing clinical laboratory services and drug development support. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.